StereotaxisSTXS
STXS
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2,469% more call options, than puts
Call options by funds: $822K | Put options by funds: $32K
185% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 13
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
14% more capital invested
Capital invested by funds: $82.4M [Q3] → $93.8M (+$11.4M) [Q4]
1% more funds holding
Funds holding: 83 [Q3] → 84 (+1) [Q4]
0.9% more ownership
Funds ownership: 47.72% [Q3] → 48.62% (+0.9%) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for STXS.
Financial journalist opinion
Based on 12 articles about STXS published over the past 30 days
Positive
Zacks Investment Research
6 days ago
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025
Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025.

Positive
Zacks Investment Research
1 week ago
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?
The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.

Neutral
GlobeNewsWire
1 week ago
Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program
ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA highlighted Stereotaxis' technology at NVIDIA GTC and has accepted Stereotaxis into the NVIDIA Connect program.

Neutral
GlobeNewsWire
3 weeks ago
Stereotaxis to Present at 37th Annual Roth Conference
ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the 37th Annual ROTH Conference in Dana Point, California.

Neutral
Zacks Investment Research
3 weeks ago
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission
STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.

Positive
Seeking Alpha
3 weeks ago
Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn
I addressed the bearish concerns some investors have. Management's conservative 2025 sales guidance set beatable targets, focusing on the existing system backlog and MAGiC usage in Europe. MAGiC Sweep will generate significant recurring revenue per procedure and expand the advantages of using robotics in EP.

Negative
Zacks Investment Research
4 weeks ago
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval
Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.

Neutral
Seeking Alpha
4 weeks ago
Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript

Negative
Zacks Investment Research
4 weeks ago
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.

Neutral
GlobeNewsWire
4 weeks ago
Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulatory submission for the first robotically navigated catheter designed to expand usage of Robotic Magnetic Navigation into the broader endovascular field.

Charts implemented using Lightweight Charts™